These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. Xu Q, Wang C, Meng Q, Liu Q, Sun H, Peng J, Ma X, Kaku T, Liu K. Eur J Pharm Sci; 2013 Mar 12; 48(4-5):650-7. PubMed ID: 23313623 [Abstract] [Full Text] [Related]
9. OAT3 Participates in Drug-Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8-A Metabolite of Bentysrepinine-In Rats and Humans In Vitro. Zhang A, Yang F, Yuan Y, Li C, Huo X, Liu J, Zhou S, Li W, Zhang N, Liu J, Dong S, Fan H, Peng Y, Zheng J. Molecules; 2023 Feb 20; 28(4):. PubMed ID: 36838982 [Abstract] [Full Text] [Related]
13. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Akiyama H, Kudo S, Shimizu T. Arzneimittelforschung; 1985 Feb 20; 35(7A):1133-40. PubMed ID: 4074424 [Abstract] [Full Text] [Related]
16. Renal organic anion transporters OAT1 and OAT3 mediate the cellular accumulation of 5-sulfooxymethylfurfural, a reactive, nephrotoxic metabolite of the Maillard product 5-hydroxymethylfurfural. Bakhiya N, Monien B, Frank H, Seidel A, Glatt H. Biochem Pharmacol; 2009 Aug 15; 78(4):414-9. PubMed ID: 19394312 [Abstract] [Full Text] [Related]